Adhesion Prevention
Genzyme Biosurgery designed the Sepra™ family of products to prevent or reduce adhesions in abdominal and pelvic surgery, and nasal and sinus surgery.
Adhesion Prevention with Seprafilm®
For adhesion prevention in abdominal and pelvic surgery, surgeons use Seprafilm Adhesion Barrier. More>
Adhesion Prevention in the Nasal Cavity with Seprapack® and Sepragel® Sinus
Seprapack and Sepragel Sinus are indicated for use in patients undergoing nasal/sinus surgery as a space-occupying stent to separate and prevent adhesions between mucosal surfaces in the nasal cavity, to help control minimal bleeding following surgery or nasal trauma, and to prevent lateralization of the middle turbinate during the postoperative period.
Please see the Package Inserts to the right for full prescribing information.
|
|
 |
Highlight |
|
|
Adhesion Barriers Recognized by Medicare and Medicaid
The Centers for Medicare and Medicaid Services (CMS), in conjunction with the National Center for Health Statistics, has issued a new International Classification of Disease (9th Edition) code for the application and administration of an adhesion barrier. The ICD-9 code 99.77 (application and administration of an adhesion barrier substance) went into effect October 1, 2002. An ICD-9 code indicates that the government now recognizes that there is regular use of adhesion barriers during surgery, based on current literature and real clinical experience. |
|
|
|
|
CONTACT INFORMATION: |
|
For more information, or to order Seprafilm, call 800-261-1570.
For more information, or to order Seprapack and Sepragel Sinus, call Gyrus ENT Customer Service at 800-773-4301.
|
|
|
|
Genzyme Corporate
